Clinical Trials Directory

Trials / Completed

CompletedNCT01178164

Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
137 (actual)
Sponsor
University Hospital, Bordeaux · Academic / Other
Sex
All
Age
6 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Fabry disease (FD) is a rare X-linked multisytemic lysosomal disorder caused by alpha-galactosidase deficiency. Globotriaosylcéramide (Gb3) deposits are observed in almost all tissues examined. Signs of the disease appear earlier and are more severe in affected males than in females. Myocardiopathy, renal failure and neurological signs including chronic pain and peripheral neuropathies are the most frequent signs. The availability of two enzymatic replacement therapies now provides a specific and effective treatment for patients. The prevalence of FD is estimated between 1/40,000 and 1/117,000. The frequency of Fabry disease has previously been estimated in several series of patients presenting one single sign, ie renal failure, hypertrophic myocardiopathy and early onset stroke. However, no data are available about the prevalence of FD in populations of patients suffering from chronic pains of unknown origin. The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Lidove et al. 2007). The patients in whom the diagnosis of FD is established during this study, will be call in for an additional visit in the Investigating Centre in order to confirm the diagnosis and propose suitable assessment and care.

Conditions

Interventions

TypeNameDescription
GENETICBlood sampling for biological and genetic analysis* Clinical examination * Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.

Timeline

Start date
2010-09-01
Primary completion
2012-09-01
Completion
2012-09-01
First posted
2010-08-10
Last updated
2013-04-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01178164. Inclusion in this directory is not an endorsement.